References
- Bhasin S, Cunningham GR, Hayes FJ, et al Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010;95:2536–59
- Garnick MB. Testosterone replacement therapy faces FDA scrutiny. JAMA 2015;313:563–4
- Gentry J, Price DJ, Peiris AN. Hypogonadism in primary care: the lowdown on low testosterone. South Med J 2013;106:492
- Vigen R, O'Donnell CI, Baron AE, et al Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA 2013;310:1829–36
- Finkle WD, Greenland S, Ridgeway GK, et al Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One 2014;9:e85805
- Shores MM, Smith NL, Forsberg CW, et al Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab 2012;97:2050–8
- Baillargeon J, Urban RJ, Kuo YF, et al Risk of myocardial infarction in older men receiving testosterone therapy. Ann Pharmacother 2014;48:1138–44
- Ontario Drug Policy Research Network. Testosterone in the treatment of androgen deficiency: Systematic review and network meta-analysis. Available from: http://odprn.ca/wp-content/uploads/2014/12/114-TRT-systematic-review-final-Nov-17-2.pdf [last accessed 20 Jan 2016]
- U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke with use. U.S. Food and Drug Administration Available from: http://www.fda.gov/Drugs/DrugSafety/ucm436259.htm [last Accessed 20 Mar 2015]
- European Medicines Agency. No consistent evidence of an increased risk of heart problems with testosterone medicines. European Medicines Agency. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Testosterone_31/Position_provided_by_CMDh/WC500177617.pdf [last accessed 20 Jan 2016]
- Baillargeon J, Urban RJ, Ottenbacher KJ, et al Trends in androgen prescribing in the United States, 2001 to 2011. JAMA Intern Med 2013;173:1465–6
- Piszczek J, Mamdani M, Antoniou T, et al The impact of drug reimbursement policy on rates of testosterone replacement therapy among older men. PLoS One 2014;9:e98003
- Hall SA, Ranganathan G, Tinsley LJ, et al Population-based patterns of prescription androgen use, 1976–2008. Pharmacoepidemiol Drug Saf 2014;23:498–506
- Brand TC, Canby-Hagino E, Thompson IM. Testosterone replacement therapy and prostate cancer: a word of caution. Curr Urol Rep 2007;8:185–9
- Harman SM. Testosterone in older men after the Institute of Medicine Report: where do we go from here? Climacteric 2005;8:124–35
- Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med 2013;11:108
- Corona G, Maseroli E, Rastrelli G, et al Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. Expert Opin Drug Saf 2014;13:1327–51
- Ontario Drug Policy Research Network. Testosterone replacement therapy: environmental scan and local historical context. Available from: http://45.55.179.43/wp-content/uploads/2014/12/111-TRT-Environmental-scan-final-dec-01.pdf [last accessed 14 Jan 2015]
- Martins DFK, Yao Z, Singh S, et al Testosterone replacement therapy. Available from: http://45.55.179.43/wp-content/uploads/2014/12/112-TRT-Pharmacoepi-final-report-CENSORED-04dec14.pdf [last accessed 14 Jan 2015]
- Wells GEJ, Kelly S, Peterson J, et al Testosterone in the treatment of androgen deficiency: systematic review and network meta-analysis. Available from: http://45.55.179.43/wp-content/uploads/2014/12/114-TRT-systematic-review-final-Nov-17-2.pdf [last accessed 14 Jan 2015]
- Coyle DLK, Sabarre KA, Tingley K. Testosterone replacement therapy: pharmacoeconomics unit. Available from: http://45.55.179.43/wp-content/uploads/2014/12/113-TRT-Pharmacoeconomics-Report-FINAL.pdf [last accessed 14 Jan 2015]
- Lewis RJS, O’Conner W. Carrying out qualitative analysis. In: Ritchie J, Lewis J, eds. Qualitative research practice: a guide for social science students and researchers. Thousand Oaks (CA): Sage; 2003:219–62
- Smith J, Firth J. Qualitative data analysis: the framework approach. Nurse Res 2011;18:52–62
- Evans D. Hierarchy of evidence: a framework for ranking evidence evaluating healthcare interventions. J Clin Nurs 2003;12:77–84
- Guest G, Namey EE, Mitchell ML. Collecting qualitative data: a field manual for applied research. Califorinia: Sage; 2013:1–60
- Johnson RB, Christensen L. Educational research quantitative, qualitative, and mixed approaches. 5th ed. California: Sage; 2013:271
- Kuzel AJ. Sampling in qualitative inquiry. In: Crabtree BF, Miller WL, eds. Doing qualitative research. 2nd ed. Thousand Oaks (CA): Sage; 1999:33–45
- Morgan S, Kennedy J, Boothe K, et al Toward an understanding of high performance pharmaceutical policy systems: a “triple-a” framework and example analysis. Open Health Serv Policy J 2009;2:1–9
- Gooren LJ, Behre HM. Diagnosing and treating testosterone deficiency in different parts of the world: changes between 2006 and 2010. Aging Male 2012;15:22–7
- Hanus M, Matouskova M, Starka L, Hill M. [Hormones and quality of life in aging men]. Cas Lek Cesk 2003;142:157–63
- Holm AC, Fredrikson MG, Theodorsson E, et al Change in testosterone concentrations over time is a better predictor than the actual concentrations for symptoms of late onset hypogonadism. Aging Male 2011;14:249–56
- Lackner JE, Rucklinger E, Schatzl G, et al Are there symptom-specific testosterone thresholds in aging men? BJU Int 2011;108:1310–15
- Morley JE, Perry HM III, Kevorkian RT, Patrick P. Comparison of screening questionnaires for the diagnosis of hypogonadism. Maturitas 2006;53:424–9
- Casulari LA, Motta LD. Diagnostic of andropause: a problem not yet solved. Arq Bras Endocrinol Metabol 2008;52:1401–2
- Pommerville PJ, Zakus P. Andropause: knowledge and awareness among primary care physicians in Victoria, BC, Canada. Aging Male 2006;9:215–20
- Katz A, Katz A, Burchill C. Androgen therapy: testing before prescribing and monitoring during therapy. Can Fam Physician 2007;53:1936–42
- Dohle GRAS, Bettocchi C, Kliesch S, et al Guidelines on male hypogonadism. Agency for Healthcare Research and Quality (AHRQ). Available from: http://www.guideline.gov/content.aspx?id=37626 [last accessed 15 Mar 2015]
- Wang C, Nieschlag E, Swerdloff R, et al Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Eur J Endocrinol 2008;159:507–14
- Lunenfeld B, Mskhalaya G, Zitzmann M, et al Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. Aging Male 2015;18:5–15
- Dean J, McMahon CG, Guay AT, et al The International Society for Sexual Medicine’s Process of Care for the Assessment and Management of Testosterone Deficiency in Adult Men. J Sex Med 2015;12:1660–86
- Anderson JK, Faulkner S, Cranor C, et al Andropause: knowledge and perceptions among the general public and health care professionals. J Gerontol A Biol Sci Med Sci 2002;57:M793–6
- Yan YY. Awareness and knowledge of andropause among Chinese males in Hong Kong. Am J Mens Health 2010;4:231–6
- Gan EH, Pattman SSHSP, Quinton R. A UK epidemic of testosterone prescribing, 2001–2010. Clin Endocrinol (Oxf) 2013;79:564–70
- Handelsman DJ. Global trends in testosterone prescribing, 2000–2011: expanding the spectrum of prescription drug misuse. Med J Aust 2013;199:548–51
- Braun SR. Promoting “low T”: a medical writer's perspective. JAMA Intern Med 2013;173:1458–60
- Guest G, Bunce A, Johnson L. How many interviews are enough?: An experiment with data saturation and variability. Field Methods 2006;18:59–82
- Sader MA, Griffiths KA, Skilton MR, et al Physiological testosterone replacement and arterial endothelial function in men. Clin Endocrinol (Oxf) 2003;59:62–7